Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APJ Parenteral
- Development stage
- Preclinical
- Lead developer
- BioAge Labs
- Modality
- Peptides, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
APJ Parenteral is a long-acting biologic agonist of the apelin receptor (APJ) currently in preclinical development by BioAge Labs for the treatment of obesity. Designed as an 'exercise mimetic,' the drug targets the apelin pathway to replicate the metabolic benefits of physical activity, such as increased energy expenditure and improved muscle function. It is intended for once-weekly subcutaneous administration, particularly in combination with incretin-based therapies like GLP-1 receptor agonists. Preclinical studies have demonstrated that adding APJ agonism to GLP-1 therapy can significantly enhance weight loss while preserving lean muscle mass and restoring healthy body composition. The program includes a nanobody candidate licensed from JiKang Therapeutics, with an Investigational New Drug (IND) application planned for 2026.
- Other names
- APJ agonist biologicAPJ agonist nanobody
02
Targets
APLNR (Apelin receptor)
Beyond the preview
Go deeper on APJ Parenteral.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APJ Parenteral.